• Users Online: 663
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2018  |  Volume : 9  |  Issue : 1  |  Page : 1-5

Hydroxyurea: Modifier of pathophysiology in sickle cell anemia


1 Department of Hematology and Blood Transfusion, Lagos State University College of Medicine, PMB 21266, Ikeja, Nigeria
2 Department of Hematology and Blood Transfusion, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria

Correspondence Address:
Akinsegun Akinbami
Department of Hematology and Blood Transfusion, Lagos State University College of Medicine, PMB 21266, Ikeja, Lagos
Nigeria
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/atp.atp_31_17

Get Permissions

Sickle cell anemia (SCA) patients have a point mutation in the 6th codon of the hemoglobin gene in which adenine is replaced by thymine resulting in replacement of glutamic acid with valine on the 6th amino acid in the β globin chain of the hemoglobin. Despite identical basic genetic mutation in all SCA patients, significant variation in clinical severity occurs. Clinical severity of SCA varies from mild to very severe types requiring more intensive medical interventions such as use of hydroxyurea (HU) and stem cell transplantation. Use of HU has improved clinical outcome in SCA and is recommended for moderate-to-severe varieties of SCA. This review brings to the fore mode of action, indications, commencement of therapy, monitoring, toxicity, and discontinuation of HU in selected SCA patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed575    
    Printed79    
    Emailed1    
    PDF Downloaded138    
    Comments [Add]    

Recommend this journal